Skip to content

Vaginal Ovule With Flavonoid Tea Extract for the Correction of Imbalance in the Vaginal Environment

Medical Device Matuzalem Flavonoid Tea Extract Vaginal Ovule for the Correction of the Imbalance in the Vaginal Environment- Prospective, Multicentric, Two-arm, Randomized, Vehicle-controlled, Blinded, Comparative Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04171947
Acronym
MAT072017
Enrollment
274
Registered
2019-11-21
Start date
2017-12-04
Completion date
2018-05-09
Last updated
2019-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Flora Imbalance, Vaginosis, Bacterial

Keywords

Tea, Polyphenols, Nugent score, Antioxidants, Vaginal pH, complementary medicine

Brief summary

Randomized, blinded vehicle-controlled multicenter clinical trial (MAT072017) to determine the effect of vaginal ovules containing 2 mg of the tea extract Matuzalem on the subjective symptoms (5-point scale pruritus (itching), dolor (pain), rubor (redness), fluor (discharge), and fetor (odor)), and objective symptoms (pH, Nugent score) of bacterial vaginosis. An ovule containing only the vehicle (polyethylene glycol 3000 S) was used as a control. The study was blinded from the perspective of the subject, investigator, laboratory personnel and data analyst.

Detailed description

The objective was to determine whether vaginal ovule with tea extract once-daily for 5-7 days improves symptoms of intermediate vaginal flora and prevents the development of bacterial vaginosis. Composite primary endpoint designed as a drop in the Nugent score, vaginal pH, or improvement of subjective symptoms was compared between the active and vehicle (polyethylene-glycol) arm after 7 days of application and following 7 days after the application. Secondary outcome measures were (1) Correction of the vaginal environment (as previously defined) 7 days after the completion of the prescribed 7-day regimen (day 14); (2) change in each parameter separately; (3) change in individual subjective symptoms, (4) exploratory analysis of the microbial environment at each subject visit. The study was approved and supervised by the National authority and Ethics committee and prospectively registered in the Czech national medical device trial registry RZPRO and the European medical device trial registry EUDAMED.

Interventions

DEVICEMatuzalem ovule

vaginal ovule with 2 mg tea extract

DEVICEVehicle ovule

polyethylene glycol vaginal ovule

Sponsors

Matuzalem.com-cz, s.r.o.
CollaboratorUNKNOWN
Value Outcomes Ltd.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

blinded from the perspective of the participant, investigator, laboratory analyst and data analyst

Intervention model description

vehicle-controlled two-arm

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* premenopausal participants * disturbed vaginal environment * not in need of antibiotic or antimycotic treatment * participants were citizens of the Czech Republic * age between 18 and 55 years * either a vaginal pH \> 4.5 or/and vaginal discomfort * able to follow the prescribed regimen * informed consents prior to any intervention, including diagnostic procedures.

Exclusion criteria

* no vaginal bleeding of unknown aetiology * hypersensitivity * pregnancy * lactation * period during enrollment * antibiotics in the previous 30 days * treated with any products with similar indication * acute urogenital infection * diabetes mellitus * advanced oncologic disease * participant to other trial * Nugent score above 6

Design outcomes

Primary

MeasureTime frameDescription
Composite endpoint (vaginal pH, Nugent score, subjective symptoms via questionnaire) after treatment completionfollowing 7 days of the ovule daily applicationCorrection of the vaginal environment after 7 days of once-daily application of the ovule was defined as: a drop-in Nugent score to \< 4 and/or a drop in vaginal pH to \< 4.5, or a subjective improvement in at least 2 symptoms by at least 2 points on a 5-point scale in patients whose baseline pH was \< 4.5 and NS \< 4. Subjective symptoms: Pruritus, dolor, rubor, fluor and fetor reported by the patient on 5-point scale (0=no problem to 4=severe problem)

Secondary

MeasureTime frameDescription
Change in the subjective symptoms (questionnaire) after treatment completionfollowing 7 days of the ovule daily applicationPruritus, dolor, rubor, fluor and fetor reported by the patient on 5-point scale (0=no problem to 4=severe problem)
Change in the pH alone after 7 days since treatment completion7 days after the completion of the 7-day treatmentCorrection of the pH measured via pH strips
Composite endpoint (vaginal pH, Nugent score, subjective symptoms via questionnaire) after 7 days since treatment completion7 days after the completion of the 7-day treatmentCorrection of the vaginal environment after 7 days after treatment completion defined as: a drop-in NS to \< 4 and/or a drop in vaginal pH to \< 4.5, or a subjective improvement in at least 2 symptoms by at least 2 points on a 5-point scale in patients whose baseline pH was \< 4.5 and NS \< 4. Subjective symptoms: Pruritus, dolor, rubor, fluor and fetor reported by the patient on 5-point scale (0=no problem to 4=severe problem)
Change in the pH alone after treatment completionfollowing 7 days of the ovule daily applicationCorrection of the pH measured via pH strips
Change in the Nugent score alone after treatment completionfollowing 7 days of the ovule daily applicationNugent score determined under 1000x magnification
Change in the subjective symptoms (questionnaire) 7 days after treatment completion7 days after the completion of the 7-day treatmentPruritus, dolor, rubor, fluor and fetor reported by the patient on 5-point scale (0=no problem to 4=severe problem)
Exploratory analysis of the microbial environment after treatment completion: squamous epithelial cellsfollowing 7 days of the ovule daily applicationQuantification of: squamous epithelial cells under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: squamous epithelial cells7 days after the completion of the 7-day treatmentQuantification of: squamous epithelial cells under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: clue cellsfollowing 7 days of the ovule daily applicationQuantification of clue cells under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: clue cells7 days after the completion of the 7-day treatmentQuantification of clue cells under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: mixed florafollowing 7 days of the ovule daily applicationQuantification of mixed flora under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: mixed flora7 days after the completion of the 7-day treatmentQuantification of mixed flora under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: yeast as pseudomyceliafollowing 7 days of the ovule daily applicationQuantification of yeast as pseudomycelia under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: yeast as pseudomycelia7 days after the completion of the 7-day treatmentQuantification of yeast as pseudomycelia under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: Gram negative diplococcifollowing 7 days of the ovule daily applicationQuantification of: Gram negative diplococci under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: Gram negative diplococci7 days after the completion of the 7-day treatmentQuantification of: Gram negative diplococci under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: fibrous Lactobacillusfollowing 7 days of the ovule daily applicationQuantification of: fibrous Lactobacillus under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: fibrous Lactobacillus7 days after the completion of the 7-day treatmentQuantification of: fibrous Lactobacillus under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: Gardnerellafollowing 7 days of the ovule daily applicationQuantification of: Gardnerella under 1000x magnification
Change in the Nugent score alone 7 days after treatment completion7 days after the completion of the 7-day treatmentNugent score determined under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: spirochetesfollowing 7 days of the ovule daily applicationQuantification of: spirochetes under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: spirochetes7 days after the completion of the 7-day treatmentQuantification of: spirochetes under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: parabasal epithelial cellsfollowing 7 days of the ovule daily applicationQuantification of: parabasal epithelial cells under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: parabasal epithelial cells7 days after the completion of the 7-day treatmentQuantification of: parabasal epithelial cells under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: leukocytesfollowing 7 days of the ovule daily applicationQuantification of: leukocytes under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: leukocytes7 days after the completion of the 7-day treatmentQuantification of: leukocytes under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: yeast as blastosporesfollowing 7 days of the ovule daily applicationQuantification of: yeast as blastospores under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: yeast as blastospores7 days after the completion of the 7-day treatmentQuantification of: yeast as blastospores under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: Gram pos. cocci in chainsfollowing 7 days of the ovule daily applicationQuantification of: Gram pos. cocci in chains under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: Gram pos. cocci in chains7 days after the completion of the 7-day treatmentQuantification of: Gram pos. cocci in chains under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: Lactobacillusfollowing 7 days of the ovule daily applicationQuantification of: Lactobacillus under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: Lactobacillus7 days after the completion of the 7-day treatmentQuantification of: Lactobacillus under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: Mobilincusfollowing 7 days of the ovule daily applicationQuantification of: Mobilincus under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: Mobilincus7 days after the completion of the 7-day treatmentQuantification of: Mobilincus under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: Leptotrichiafollowing 7 days of the ovule daily applicationQuantification of: Leptotrichia under 1000x magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: Leptotrichia7 days after the completion of the 7-day treatmentQuantification of: Leptotrichia under 1000x magnification
Exploratory analysis of the microbial environment after treatment completion: Trichomonas vaginalisfollowing 7 days of the ovule daily applicationQuantification of: Trichomonas vaginalis under 1000 magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: Trichomonas vaginalis7 days after the completion of the 7-day treatmentQuantification of: Trichomonas vaginalis under 1000 magnification
Exploratory analysis of the microbial environment after 7 days after treatment completion: Gardnerella7 days after the completion of the 7-day treatmentQuantification of: Gardnerella under 1000x magnification

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026